Resources

Pulmonary Arterial Hypertension Causes and Treatments

Research Objectives:

  • Understand the current pulmonary arterial hypertension (PAH) patient and treatment landscape
  • Explore physician understanding of new treatments in development for PAH and their expectations

Methodology:
Method: 8-minute MicroSurvey via InCrowd
Crowds: US Cardiologists, US Pulmonologists
Sample Size: n=50
Fielding Period: January 30, 2019
Screening Criteria: Qualified respondents are US-based Cardiologists and Pulmonologists who…
• Have at least five PAH patients under their care
• Are aware of products in development for the treatment of PAH

Two key findings:

  • Most physicians feel that increased patient survival, improved health-related quality of life, and improved functional class are the most important clinical trial endpoints for new PAH treatments.
  • Almost half of physicians agree that the ideal mechanism of action (MOA) for new PAH drugs in development should be selective pulmonary vasodilation.

Download the full report now!

Please fill out the form below to access this content

Name(Required)
Consent
This field is for validation purposes and should be left unchanged.

Related Resources

Why Diversity Matters to Patients

Why Diversity Matters to Patients

How does a diverse patient audience feel about representation among their own physicians? Is the diversity outlook improving among healthcare professionals? Find out in our latest report from the 2023 Pharma Market Research Conference. We examined: Satisfaction with...

read more
ASH 2022 Real-Time Round-Up

ASH 2022 Real-Time Round-Up

The 2022 Annual Meeting of the American Society of Hematology (ASH) took place in person from December 10th to the 13th. InCrowd wanted to learn from those Hematologists and Hematology-Oncologists who attended these two objectives: Explore which condition had the most...

read more